Changing Landscape of Treatment Options for Multiple Myeloma

Released On
October 5, 2020

Expires On
October 5, 2021

Media Type

Completion Time
3.25 hours

Hematology-Oncology, Radiation Oncology, Internal Medicine

Multiple Myeloma

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by CancerNet, LLC and Amedco, LLC.

Supported by an educational grant from Amgen Inc. and Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 3.25 AMA PRA Category 1 Credit(s)
  • Nurses — 3.25 Nursing Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, physician assistants, nurse practitioners, nurses involved in the treatment of patients with multiple myeloma.

Statement of Need/Program Overview

This activity will cover topics on the diagnosis, treatment, and management of patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Outline the classification and treatment of smoldering multiple myeloma (MM)
  • Develop individualized treatment plans for MM patients based on cytogenetic and genomic data
  • Identify the benefits and risks of frontline therapy for MM
  • Customize the consolidation and maintenance therapy options for MM
  • Summarize the role of sequencing therapies in relapsed MM
  • Recognize the role of geriatric assessments and their use in MM
  • Assess the potential of CAR-T cell and future therapies in MM


Keith Stewart, MBChB, MRCP

Vice President
Cancer and Director of the Princess Margaret Cancer Program, UHN
Regional Vice-President
Toronto Central South Regional Cancer Program
Ontario Health
Toronto, Canada

Joseph Mikhael, MD

Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute (TGen)
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Scottsdale, AZ

Amrita Krishnan, MD

Judy and Bernard Briskin Center for Multiple Myeloma Research
Department of Hematology & Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center
Duarte, CA

Ajai Chari, MD

Professor of Medicine
Director of Clinical Research in the Multiple Myeloma Program
Associate Director of Clinical Research
Mt Sinai Cancer Clinical Trials Office
Mount Sinai Hospital
New York, NY

Tanya M. Wildes, MD, MSCI

Associate Professor of Medicine
Division of Medical Oncology
Washington University School of Medicine
660 South Euclid Avenue
St Louis, MO

Nina Shah, MD

Associate Professor
Department of Medicine
San Francisco, CA

Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1.00 AMA PRA Category 3.25 Credits™ for physicians and 3.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest and have been resolved (C7 SCS 6.1-¬‐6.2, 6.5). All individuals in a position to control the content of CE are listed below.

Keith Stewart, MBChB, MRCP

  • Consultancy or Honoraria: Amgen; Bristol-Meyers Squibb; Celgene; GSK, Janssen; Ono, Oncopeptide; Roche/Genentech, Sanofi Aventis
  • Membership on a Board or Advisory Committee: Genomics England; Tempus
  • Discussion of off-label drug use: Venetoclax

Joseph Mikhael, MD

  • Consultant: Amgen, Celgene, GSK, Janssen, Karyopharm, Sanofi Genzyme, Takeda Oncology

Amrita Krishnan, MD

  • Consultant: BMS, Karyopharma, Adaptive, Regeneron, Janssen, Sutro
  • Speaker’s Bureau: BMS, Takeda

Ajai Chari, MD

  • Research Support/P.I.: Amgen, Array Biopharma, Celgene, Glaxo Smith Klein, Janssen, Millenium/Takeda, Novartis Pharmaceuticals, Oncoceutics, Pharmacyclics, Seattle Genetics
  • Consultant: Amgen, Bristol Myers Squibb, Celgene, Millenium/Takeda, Janssen, Karyopharm
  • Scientific Advisory Board: Amgen, Celgene, Millenium/Takeda, Janssen, Karyopharm, Sanofi, Seattle Genetics

Tanya M. Wildes, MD, MSCI

  • Research Funding: Janssen
  • Consultant: Carevive Systems, Seattle Genetics

Nina Shah, MD

  • Consultant: GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDX, Kite, Karyopharm
  • Research Funding: GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm

Planners and Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

  • Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships.
  • Brian Waggoner (CancerNet, LLC) has no relevant financial relationships to disclose.
  • Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.


Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant


Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Amedco and CancerNet require that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Amedco makes every effort to develop CME/CE activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME/CE questions, please contact: Amedco at:

For questions regarding content, please contact: CancerNet at